Frexalimab
EFC18098
Phase 3 small_molecule active
Quick answer
Frexalimab for Multiple Sclerosis is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Multiple Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active